{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T17:55:38Z","timestamp":1782755738099,"version":"3.54.5"},"reference-count":34,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2017-0443_s_999_w2aab3b7d106b1b6b1aab1c15b1Aa\">\n                  <jats:title>Background:<\/jats:title>\n                  <jats:p>Soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) ratio has been proven to predict preeclampsia occurrence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2017-0443_s_998_w2aab3b7d106b1b6b1aab1c15b2Aa\">\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>Blood samples from 195 pregnant women with suspected preeclampsia were obtained at obstetric triage admission or from the high-risk pregnancy outpatient office. Serum PlGF and sFlt-1 were measured by an electrochemiluminescence immunoassay (ECLIA) on the immunoanalyser Cobas e601 (Roche Diagnostics) and the corresponding ratio was calculated. Final outcomes were reviewed by an independent obstetrician. Only the first determination was considered.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2017-0443_s_997_w2aab3b7d106b1b6b1aab1c15b3Aa\">\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>A sFlt-1\/PlGF ratio of 38 or lower ruled out the need for pregnancy termination due to preeclampsia in the subsequent week with a negative predictive value (NPV) of 99.1% (sensitivity 97.1% and specificity 67.5%). None of the 76 pregnancies with first determination of an sFlt-1\/PlGF ratio of 38 or lower between 24 and 34 weeks of gestation delivered due to early-onset preeclampsia. Positive likelihood ratio (PLR) of an sFlt-1\/PlGF ratio above 38 for prediction of pregnancy termination due to preeclampsia within 4 weeks is analogous to published evidence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2017-0443_s_996_w2aab3b7d106b1b6b1aab1c15b4Aa\">\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p>Between 24 and 34 weeks of gestation, no subsequent determination was needed to completely rule out early-onset preeclampsia when the first sFlt-1\/PlGF ratio determination was 38 or lower in singleton pregnancies with signs or symptoms of this syndrome. These findings, if confirmed, will reduce costs and facilitate the implementation of the sFlt-1\/PlGF ratio in women with clinical suspicion of preeclampsia in the third trimester.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2017-0443","type":"journal-article","created":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T10:01:33Z","timestamp":1503655293000},"page":"303-311","source":"Crossref","is-referenced-by-count":12,"title":["Use of the sFlt-1\/PlGF ratio to rule out preeclampsia requiring delivery in women with suspected disease. Is the evidence reproducible?"],"prefix":"10.1515","volume":"56","author":[{"given":"Enric","family":"Sabri\u00e0","sequence":"first","affiliation":[{"name":"Obstetric and Gynecology Service, Hospital-Resid\u00e8ncia Sant Camil , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma","family":"Lequerica-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Biochemistry Service , Laboratory Medicine , Hospital Universitario Central de Asturias , Oviedo , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula Lafuente","family":"Ganuza","sequence":"additional","affiliation":[{"name":"Biochemistry Service , Laboratory Medicine , Hospital Universitario Central de Asturias , Oviedo , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin Eguia","family":"\u00c1ngeles","sequence":"additional","affiliation":[{"name":"Biochemistry Service , Laboratory Medicine , Hospital Universitario Central de Asturias , Oviedo , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana I.","family":"Escudero","sequence":"additional","affiliation":[{"name":"Obstetric and Gynecology Service , Hospital Universitario Central de Asturias , Oviedo , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Mart\u00ednez-Morillo","sequence":"additional","affiliation":[{"name":"Biochemistry Service , Laboratory Medicine , Hospital Universitario Central de Asturias , Oviedo , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco V.","family":"Alv\u00e1rez","sequence":"additional","affiliation":[{"name":"Biochemistry Service , Laboratory Medicine , Hospital Universitario Central de Asturias , Oviedo , Spain"},{"name":"Servicio de Bioqu\u00edmica Cl\u00ednica , Laboratorio de Medicina , Hospital Universitario Central de Asturias , Avenida de Roma, s\/n, 33011 , Oviedo , Spain"},{"name":"Department of Biochemistry and Molecular Biology , Universidad de Oviedo , Oviedo , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2017,8,25]]},"reference":[{"key":"2021021300550957922_j_cclm-2017-0443_ref_001_w2aab3b7d106b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Duley L. The global impact of preeclampsia and eclampsia. Semin Perinatol 2009;33:130\u20137.","DOI":"10.1053\/j.semperi.2009.02.010"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_002_w2aab3b7d106b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Montquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in pregnancy (ISSHP). Hypertens Pregnancy 2001;20:XI\u2013XIV.","DOI":"10.3109\/10641950109152635"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_003_w2aab3b7d106b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet 2008;371:75\u201384.","DOI":"10.1016\/S0140-6736(08)60074-4"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_004_w2aab3b7d106b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"McClure JH, Cooper GM, Clutton-Brock TH. Saving mothers\u2019 lives: reviewing maternal deaths to make motherhood safer: 2006-8: a review. Br J Anaesth 2011;107:127\u201332.","DOI":"10.1093\/bja\/aer192"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_005_w2aab3b7d106b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Schutte J, Steegers E, Schuitemaker N, Santema J, de Boer K, Pel M, et al. Rise in maternal mortality in the Netherlands. Br J Obstet Gynaecol 2010;117:399\u2013406.","DOI":"10.1111\/j.1471-0528.2009.02382.x"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_006_w2aab3b7d106b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989;161:1200\u20134.","DOI":"10.1016\/0002-9378(89)90665-0"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_007_w2aab3b7d106b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Powe CE, Levine RJ, Karumanchi SA. Preeclampsia a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011;123:2856\u201369.","DOI":"10.1161\/CIRCULATIONAHA.109.853127"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_008_w2aab3b7d106b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Romero R, Chaiworapongsa T. Preeclampsia: a link between trophoblast dysregulation and an antiangiogenic state. J Clin Invest 2013;123:2775\u20137.","DOI":"10.1172\/JCI70431"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_009_w2aab3b7d106b1b6b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992\u20131005.","DOI":"10.1056\/NEJMoa055352"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_010_w2aab3b7d106b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649\u201358.","DOI":"10.1172\/JCI17189"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_011_w2aab3b7d106b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Chaiworapongsa T, Chaemsaithong P, Yeo L, Romero R. Preeclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol 2014;10:466\u201380.","DOI":"10.1038\/nrneph.2014.102"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_012_w2aab3b7d106b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, et al. The sFlt-1\/PlGF ratio in different types of hypertensive pregnancies disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012;206:58.e1\u201358.e8.","DOI":"10.1016\/j.ajog.2011.07.037"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_013_w2aab3b7d106b1b6b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, et al. An automated method for the determination of the sFlt-1\/PlGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010;202:161.e1\u2013161.e11.","DOI":"10.1016\/j.ajog.2009.09.016"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_014_w2aab3b7d106b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factor and the risk of preeclampsia. N Engl J med 2004;350:672\u201383.","DOI":"10.1056\/NEJMoa031884"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_015_w2aab3b7d106b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Lavine RJ, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012;125:911\u20139.","DOI":"10.1161\/CIRCULATIONAHA.111.054361"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_016_w2aab3b7d106b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P, et al. New gestational phase-specific cutoff values for the use of soluble fms-like tyrosine kinase 1\/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension 2014;63:346\u201352.","DOI":"10.1161\/HYPERTENSIONAHA.113.01787"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_017_w2aab3b7d106b1b6b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Alvarez-Fernandez I, Prieto B, Rodriguez V, Ruano Y, Escudero A, Alvarez FV. New biomarkers in diagnosis of early onset preeclampsia and imminent delivery prognosis. Clin Chem Lab Med 2014;52:1159\u201368.","DOI":"10.1515\/cclm-2013-0901"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_018_w2aab3b7d106b1b6b1ab2b2c18Aa","unstructured":"PlGF [package insert]. Roche Diagnostics GmbH, Mannheim, Germany. 2013-08, V 6.0."},{"key":"2021021300550957922_j_cclm-2017-0443_ref_019_w2aab3b7d106b1b6b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Zeisler H, Llurba E, Chantraine F, Vatish M, Phil D, Staff AC, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Eng J Med 2016;374:13\u201322.","DOI":"10.1056\/NEJMoa1414838"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_020_w2aab3b7d106b1b6b1ab2b2c20Aa","unstructured":"Perales A, Delgado JL, De la Calle M, Garc\u00eda-Hern\u00e1ndez JA, Escudero AI, Campillos JM, et al. sFlt-1\/PlGF for early onset pre-eclampsia prediction: STEPS (Study of Early Pre-eclampsia in Spain). Ultrasound Obstet Gynecol. In press."},{"key":"2021021300550957922_j_cclm-2017-0443_ref_021_w2aab3b7d106b1b6b1ab2b2c21Aa","unstructured":"American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Obstet Gynecol 2013;122:112\u201331."},{"key":"2021021300550957922_j_cclm-2017-0443_ref_022_w2aab3b7d106b1b6b1ab2b2c22Aa","unstructured":"Straus SE, Richardson WS, Glasziou P, Haynes RB. Diagnosis and screening. In: Evidence-based medicine: how to practice and teach EBM. 3rd ed. Oxford (UK): Elsevier, 2005:89\u201390."},{"key":"2021021300550957922_j_cclm-2017-0443_ref_023_w2aab3b7d106b1b6b1ab2b2c23Aa","unstructured":"Guyatt G, Sackett DL, Haynes RB. Evaluating diagnostic tests. In: Haynes RB, Sackett DL, Guyatt GH, et al., editors. Clinical epidemiology: how to do clinical practice research. New York (NY): Lippincott William and Wilkins, 2006:294\u20135."},{"key":"2021021300550957922_j_cclm-2017-0443_ref_024_w2aab3b7d106b1b6b1ab2b2c24Aa","doi-asserted-by":"crossref","unstructured":"Elie C, Coste J. A methodological framework to distinguish spectrum effects from spectrum biases and to assess diagnostic and screening test accuracy for patient populations: Application to the Papanicolaou cervical cancer smear test. BMC Med Res Methodol 2008;8:7.","DOI":"10.1186\/1471-2288-8-7"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_025_w2aab3b7d106b1b6b1ab2b2c25Aa","doi-asserted-by":"crossref","unstructured":"Goehring C, Perrier A, Morabia A. Spectrum bias: a quantitative and graphical analysis of the variability of medical diagnostic test performance. Stat Med 2004;23:125\u201335.","DOI":"10.1002\/sim.1591"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_026_w2aab3b7d106b1b6b1ab2b2c26Aa","doi-asserted-by":"crossref","unstructured":"Dragan I, Georgiou T, Prodan N, Akolekar R, Nicolaides KH. Screening for preeclampsia using sFlt-1\/PlGF ratio cut-off of 38 at 30\u201373 weeks\u2019 gestation. Ultrasound Obstet Gynecol 2017;49:73\u20137.","DOI":"10.1002\/uog.17301"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_027_w2aab3b7d106b1b6b1ab2b2c27Aa","doi-asserted-by":"crossref","unstructured":"Stepan H, Herraiz I, Schlembach D, Verlohren S, Brennecke S, Chantraine F, et al. Implementation of the sFlt-1\/PlGF ratio for prediction and diagnosis of preeclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet Gynecol 2015;45:241\u20136.","DOI":"10.1002\/uog.14799"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_028_w2aab3b7d106b1b6b1ab2b2c28Aa","doi-asserted-by":"crossref","unstructured":"Verlohren S, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstr\u00f6m M, et al. The sFlt-1\/PLGF ratio can rule out preeclampsia for up to four weeks in women with suspected preeclampsia. Pregnancy Hypertens 2016;6:140\u20131.","DOI":"10.1016\/j.preghy.2016.08.009"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_029_w2aab3b7d106b1b6b1ab2b2c29Aa","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Arriaga PI, Herraiz I, L\u00f3pez-Jim\u00e9nez EA, G\u00f3mez-Montes E, Denk B, Galindo A. Uterine artery Doppler and sFlt-1\/PlGF ratio: usefulness in diagnosis of preeclampsia. Ultrasound Obstet Gynecol 2013;41:530\u20137.","DOI":"10.1002\/uog.12400"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_030_w2aab3b7d106b1b6b1ab2b2c30Aa","doi-asserted-by":"crossref","unstructured":"Schaarschmidt W, Rana S, Stepan H. The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP syndrome. J Perinat Med 2013;41:511\u20136.","DOI":"10.1515\/jpm-2012-0248"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_031_w2aab3b7d106b1b6b1ab2b2c31Aa","doi-asserted-by":"crossref","unstructured":"Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstr\u00f6m M, et al. Soluble fms-like tyrosine kinase-1-to-placental growth factor ratio and time to delivery in women with suspected preeclampsia. Obstet Gynecol 2016;128:261\u20139.","DOI":"10.1097\/AOG.0000000000001525"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_032_w2aab3b7d106b1b6b1ab2b2c32Aa","unstructured":"Frusca T, Gervasi MT, Paolini D, Dionisi M, Ferre F, Cetin I. Budget impact analysis of sFlt-1\/PlGF ratio as prediction test in Italian women with suspected preeclampsia. J Materna-Fetal Neonat Med 2016;13:1\u201314."},{"key":"2021021300550957922_j_cclm-2017-0443_ref_033_w2aab3b7d106b1b6b1ab2b2c33Aa","doi-asserted-by":"crossref","unstructured":"Vatish M, Strunz-Mckendry T, Hund M, Allegranza D, Wolf C, Smare C. sFlt-1\/PlGF ratio test for pre-eclampsia: an economic assessment for the UK. Ultrasound Obstet Gynecol 2016;48:765\u201371.","DOI":"10.1002\/uog.15997"},{"key":"2021021300550957922_j_cclm-2017-0443_ref_034_w2aab3b7d106b1b6b1ab2b2c34Aa","doi-asserted-by":"crossref","unstructured":"Lim JH, Kim SY, Park SY, Yang JH, Kim MY, Ryu HM. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstet Gynecol 2008;111:1403\u20139.","DOI":"10.1097\/AOG.0b013e3181719b7a"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/cclm.2018.56.issue-2\/cclm-2017-0443\/cclm-2017-0443.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2017-0443\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2017-0443\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T23:58:28Z","timestamp":1619049508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2017-0443\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,25]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,8,25]]},"published-print":{"date-parts":[[2018,1,26]]}},"alternative-id":["10.1515\/cclm-2017-0443"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2017-0443","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8,25]]}}}